Erigeron acid, extraction method and application thereof, and medicine for treating ischemic stroke
By extracting and purifying fenugreek acid from Erigeron breviscapus, a drug for treating ischemic stroke was prepared, which solved the problems of insufficient effectiveness and large side effects of existing drugs within the treatment window, and achieved safe and efficient treatment of ischemic stroke.
Patent Information
- Application Number
- CN202410160722.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-04
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-02-04
AI Technical Summary
Existing medications for ischemic stroke are not effective enough within the treatment window and carry the risk of bleeding. Furthermore, existing medications have significant side effects, and there is a lack of safe and effective treatment options.
Ferulic acid was extracted and purified from *Erigeron breviscapus* using a multi-step method and then applied to the preparation of drugs for treating ischemic stroke, including injections or lyophilized formulations. The purified formulation was obtained by reversed-phase chromatography using an aqueous solution of ethanol and formic acid.
Feminine has shown significant therapeutic effects in ischemic stroke, with good safety profile, and can significantly reduce cerebral ischemia volume and ischemic damage, which is superior to existing drugs.
Smart Images

Figure CN118206596B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicines, and in particular relates to ferulate acid, an extraction method and application thereof, and a medicine for treating ischemic cerebral stroke. Background Art
[0002] Cerebral stroke, also known as cerebral infarction, is characterized by high morbidity, high mortality and high disability rate. Cerebral stroke includes ischemic stroke (IS) and hemorrhagic stroke (HS). Among them, ischemic stroke accounts for a larger proportion of cerebral stroke, about 80%. The course of ischemic stroke can be divided into acute, subacute and chronic stages. Among them, effective treatment of acute ischemic stroke helps the damaged nerve tissue to restore function and avoid sequelae. The current drug mechanisms for the treatment of acute ischemic stroke mainly include thrombolysis, neuroprotection, anticoagulation and vasodilation. Recombinant tissue plasminogen activator (rt-PA) alteplase is a drug approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of IS. It is still the gold standard for the treatment of acute ischemic stroke. However, the drug can only be used within the treatment time window (3 hours), which makes more than 95% of patients unable to receive treatment and has a high risk of intracranial hemorrhage. In recent years, the new generation of therapeutic drug tenecteplase has significant advantages in the treatment of acute ischemic stroke, but the drug is only effective within the treatment window within 4.5 hours after onset, and there is a risk of bleeding and unavoidable ischemic reperfusion neurological damage (Expert Opin Investig Drugs, 2022, 31, 7, 645-667). It has not yet been approved by the FDA as a therapeutic drug for ischemic stroke. Edaravone is a neuroprotectant with an antioxidant mechanism of action. Although edaravone has a certain effect in the treatment of stroke, it has severe liver and kidney toxicity. Butylphthalide is a natural active compound found in celery seeds. It is a drug for the treatment of stroke that has been chemically synthesized and has good clinical efficacy (Front Pharmacol, 2022, 13, 963118), but the drug has side effects of bleeding tendency and liver damage. Therefore, the development of new drugs for the treatment of ischemic stroke is a technical problem that needs to be solved urgently. Summary of the invention
[0003] The purpose of the present invention is to provide the application of ferulate acid and its extraction method, and a drug for treating ischemic stroke. The ferulate acid provided by the present invention has a significant effect of treating ischemic stroke and has good safety, and can be used as a drug for treating ischemic stroke.
[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0005] The invention provides a ferruginic acid having a structure shown in formula I; the absolute configuration of the ferruginic acid is (2S, 4R, 5R, 6S, 7R)-4,8-dicaffeoyl-2,7-anhydro-3-deoxy-D-manno-2-octulose acid, and its English name is (2S, 4R, 5R, 6S, 7R)-4,8-di[(E)-caffeoyloxy]-2,7-anhydro-3-deoxy-D-manno-2-octuloso nic Acid;
[0006]
[0007] The present invention provides a method for extracting ferulate acid described in the above technical solution, comprising the following steps:
[0008] Extracting Erigeron breviscapus with 70-95wt% ethanol aqueous solution to obtain a total extract;
[0009] The total extract is loaded onto a macroporous resin column, and eluted with water and a 25 wt % ethanol aqueous solution in sequence, and the eluate obtained when eluted with the 25 wt % ethanol aqueous solution is collected;
[0010] Diluting the eluate obtained when eluting with the 25 wt % ethanol aqueous solution with water, loading the obtained dilution onto a microporous resin column, eluting with 10 wt % ethanol aqueous solution and 20 wt % ethanol aqueous solution in sequence, collecting the eluate obtained when eluting with the 20 wt % ethanol aqueous solution and concentrating to dryness to obtain a concentrate;
[0011] The concentrate is purified by reverse phase chromatography using methanol and 0.1-0.3 vol% formic acid aqueous solution in a volume ratio of 30:70 and acetonitrile and 0.1 vol% formic acid aqueous solution in a volume ratio of 15:85 as mobile phases to obtain ferruginous acid.
[0012] Preferably, the conditions for extracting Erigeron breviscapus with 70-95wt% ethanol aqueous solution include: the number of extractions is 3 times, the extraction time is 2h each time, the extraction temperature is reflux temperature each time, and the ratio of the 70-95wt% ethanol aqueous solution to Erigeron breviscapus is 700L:100kg each time.
[0013] Preferably, the macroporous resin used in the macroporous resin column is DM130.
[0014] Preferably, the microporous resin used in the microporous resin column is HP20SS.
[0015] Preferably, the concentration of ethanol in the diluent is 12.5 wt %.
[0016] Preferably, the chromatographic column used for the reverse phase chromatography purification is a dynamic axial compression column; and the filler used in the dynamic axial compression column is C-18 reverse phase separation material.
[0017] The present invention provides the use of the felibacic acid described in the above technical solution in preparing a medicine for treating ischemic cerebral stroke.
[0018] The present invention provides a medicine for treating ischemic cerebral stroke, comprising the felibacic acid described in the above technical solution and pharmaceutically acceptable excipients.
[0019] Preferably, the dosage form of the drug for treating ischemic stroke includes an injection or a lyophilized preparation.
[0020] The present invention provides a ferulate acid having a structure shown in formula I; the absolute configuration of the ferulate acid is (2S, 4R, 5R, 6S, 7R)-4, 8-dicaffeoyl-2, 7-anhydro-3-deoxy-D-manno-2-octulose acid, and the English name is (2S, 4R, 5R, 6S, 7R)-4, 8-di[(E)-caffeoyloxy]-2, 7-anhydro-3-deoxy-D-manno-2-octulosonic acid. The ferulate acid provided by the present invention has a significant effect of treating ischemic stroke in an animal model, and has good safety, and can be used as a therapeutic drug for ischemic stroke.
[0021] The invention provides a method for extracting ferulate acid, specifically extracting and separating ferulate acid from Erigeron breviscapus, thus providing a basis for its medicinal research. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0023] Figure 1 For the X-ray single crystal structure of the methyl esterified derivative of feliganoic acid in the asymmetric unit, the displacement ellipsoids were plotted at a 30% probability level;
[0024] Figure 2 For the X-ray single crystal structure of the methyl esterified derivative of feliganoic acid observed by the atomic labeling method, the displacement ellipsoids were plotted at a probability level of 30%;
[0025] Figure 3 is the molecular arrangement diagram of the methyl ester derivative of felibacteric acid (hydrogen bonds are represented by dotted lines);
[0026] Figure 4 This is the TTC staining result of MCAO model 24 hours later. DETAILED DESCRIPTION
[0027] The invention provides a ferruginic acid having a structure shown in formula I; the absolute configuration of the ferruginic acid is (2S, 4R, 5R, 6S, 7R)-4,8-dicaffeoyl-2,7-anhydro-3-deoxy-D-manno-2-octulose acid, and its English name is (2S, 4R, 5R, 6S, 7R)-4,8-di[(E)-caffeoyloxy]-2,7-anhydro-3-deoxy-D-manno-2-octuloso nic Acid;
[0028]
[0029] The present invention provides a method for extracting ferulate acid described in the above technical solution, comprising the following steps:
[0030] Extracting Erigeron breviscapus with 70-95wt% ethanol aqueous solution to obtain a total extract;
[0031] The total extract is loaded onto a macroporous resin column, and eluted with water and a 25 wt % ethanol aqueous solution in sequence, and the eluate obtained when eluted with the 25 wt % ethanol aqueous solution is collected;
[0032] Diluting the eluate obtained when eluting with the 25 wt % ethanol aqueous solution with water, loading the obtained dilution onto a microporous resin column, eluting with 10 wt % ethanol aqueous solution and 20 wt % ethanol aqueous solution in sequence, collecting the eluate obtained when eluting with the 20 wt % ethanol aqueous solution and concentrating to dryness to obtain a concentrate;
[0033] The concentrate is purified by reverse phase chromatography using methanol and 0.1-0.3 vol% formic acid aqueous solution in a volume ratio of 30:70 and acetonitrile and 0.1 vol% formic acid aqueous solution in a volume ratio of 15:85 as mobile phases to obtain ferruginous acid.
[0034] In the present invention, unless otherwise specified, the raw materials used are commercially available products well known to those skilled in the art or are prepared by methods well known to those skilled in the art.
[0035] The present invention uses 70-95wt% ethanol aqueous solution to extract Erigeron breviscapus to obtain a total extract. In the present invention, the conditions for extracting Erigeron breviscapus with 70-95wt% ethanol aqueous solution preferably include: the number of extractions is 3 times, the extraction time is 2h each time, the extraction temperature is reflux temperature each time, and the amount ratio of the 70-95wt% ethanol aqueous solution to Erigeron breviscapus is 700L:100kg each time. In the present invention, each extraction preferably includes solid-liquid separation, and the solid-liquid separation method is preferably filtration. The present invention preferably combines the liquid materials obtained from each solid-liquid separation and then concentrates them, and recovers the solvent to obtain the total extract. The present invention does not specifically limit the concentration method, and the concentration method well known to those skilled in the art can be used.
[0036] After obtaining the total extract, the present invention loads the total extract onto a macroporous resin column, and sequentially elutes with water and 25wt% ethanol aqueous solution, and collects the eluate obtained when eluting with 25wt% ethanol aqueous solution. The present invention preferably first dissolves the total extract with 95wt% ethanol aqueous solution and then loads it onto a macroporous resin column. The macroporous resin used in the macroporous resin column of the present invention is preferably DM130. The dosage ratio of the total extract to the macroporous resin of the present invention is preferably 17.2kg:319L. The present invention preferably dissolves the total extract with 95wt% ethanol aqueous solution and then mixes it with part of the macroporous resin, vacuum-dries it, and then loads it onto a macroporous resin column containing the remaining macroporous resin, and elutes it with the above-mentioned eluent; the volume ratio of the part of the macroporous resin to the remaining macroporous resin is preferably 69:250. In the present invention, the eluate obtained during water elution does not contain the main active ingredient and is directly discarded.
[0037] After collecting the eluate obtained when eluting with a 25wt% ethanol aqueous solution, the present invention dilutes the eluate obtained when eluting with the 25wt% ethanol aqueous solution with water, loads the obtained dilution onto a microporous resin column, sequentially eluting with a 10wt% ethanol aqueous solution and a 20wt% ethanol aqueous solution, collects the eluate obtained when eluting with a 20wt% ethanol aqueous solution, and concentrates it to dryness to obtain a concentrate. In the present invention, the concentration of ethanol in the dilution is preferably 12.5wt%; the microporous resin used in the microporous resin column is preferably HP20SS. The amount of the 20wt% ethanol aqueous solution used in the present invention is preferably 4 column volumes.
[0038] After obtaining the concentrate, the present invention sequentially uses methanol with a volume ratio of 30:70 and a 0.1-0.3 vol% formic acid aqueous solution as a mobile phase and acetonitrile with a volume ratio of 15:85 and a 0.1 vol% formic acid aqueous solution as a mobile phase, and performs reverse phase chromatography purification on the concentrate to obtain ferruginous acid. Specifically, the present invention first uses methanol and a formic acid aqueous solution with a volume fraction of 0.1-0.3% as a mobile phase (the volume ratio of methanol to formic acid aqueous solution is 30:70) for elution, and then uses acetonitrile and a formic acid aqueous solution with a volume fraction of 0.1% as a mobile phase (the volume ratio of acetonitrile to formic acid aqueous solution is 15:85) for elution. In the present invention, the chromatographic column used for the reverse phase chromatography purification is preferably a dynamic axial compression column; the filler used in the dynamic axial compression column is preferably a C-18 reverse separation material. In the present invention, it is preferred to weigh 100 g of sample each time when performing reverse phase chromatography purification. Specifically, the weighed sample is dissolved in a 30 wt % methanol aqueous solution and then subjected to reverse phase chromatography purification to obtain ferruginic acid.
[0039] The present invention also provides the use of the felibacic acid described in the above technical solution in preparing a medicine for treating ischemic cerebral stroke.
[0040] The present invention also provides a drug for treating ischemic stroke, comprising the ferrous acid described in the above technical solution and a pharmaceutically acceptable excipient. In the present invention, the pharmaceutically acceptable excipient preferably comprises ferrous alcohol, sodium bicarbonate and water, and the water is preferably water for injection. The dosage form of the drug for treating ischemic stroke described in the present invention preferably comprises an injection or a lyophilized agent. Taking the lyophilized agent as an example, the preparation method of the ferrous acid lyophilized agent in the present invention preferably comprises the following steps: sodium bicarbonate is dissolved in part of the water and then ferrous acid is added, and the ferrous acid is dissolved by ultrasonic treatment; then ferrous alcohol is added, the pH value is adjusted to 3-4.5 with hydrochloric acid, and filtered with a microporous filter membrane, the filtrate is mixed with the remaining water, and the filtrate is packaged and freeze-dried in turn to obtain the ferrous acid lyophilized agent. In the present invention, the mass ratio of ferrous acid, sodium bicarbonate and ferrous alcohol is preferably 1:0.154:1; the present invention has no special limitation on the amount of water, and it can be selected according to actual needs; the pH value is preferably 3.5-4. In the embodiment of the present invention, the drug for treating ischemic stroke is first prepared into a lyophilized agent, and then the lyophilized agent is prepared into an injection, which is then administered by injection.
[0041] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0042] Example 1
[0043] 100 kg of dried Erigeron breviscapus was crushed, and 95 wt% ethanol aqueous solution was added for reflux extraction for 3 times, with 700 L of 95 wt% ethanol aqueous solution used for each extraction, and the extraction time for each extraction was 2 h. The extracts obtained from the 3 extractions were combined, and the total extract obtained was concentrated and the solvent was recovered to obtain 17.2 kg of total extract;
[0044] The total extract (17.2 kg) was dissolved in 95 wt% ethanol aqueous solution and mixed with 69 L of macroporous resin (DM130) and dried in vacuo. Then, 250 L of macroporous resin was loaded into a column and the dried mixture was subjected to chromatography for preliminary separation of caffeic acid phenolic compounds. Specifically, water, 25 wt% ethanol aqueous solution and 95 wt% ethanol aqueous solution were used for elution in sequence, and the eluate obtained when eluted with 25 wt% ethanol aqueous solution was collected (the eluate obtained when eluted with water did not contain the target active ingredient and was directly discarded; the eluate obtained when eluted with 95 wt% ethanol aqueous solution was collected). The obtained eluate does not contain the target active ingredient and can be discarded after the solvent is recovered), diluting it by one time with water until the ethanol concentration in the obtained dilution is 12.5wt%, loading the dilution onto a microporous resin (HP20SS) column, eluting with 10wt% ethanol aqueous solution and 20wt% ethanol aqueous solution (4 column volumes) in sequence, collecting the eluate obtained when eluting with 20wt% ethanol aqueous solution (the eluate obtained when eluting with 10wt% ethanol aqueous solution does not contain the target active ingredient and can be discarded after the solvent is recovered) and concentrating it to dryness to obtain a concentrate (1088g);
[0045] The concentrate (1088g) was purified by reverse phase chromatography using a Hanbang industrial preparative liquid phase system, wherein the chromatographic column used was a dynamic axial compression column (DAC), specifically, 10kg of C-18 reverse separation material was loaded into the dynamic axial compression column, 100g of the concentrate (1088g) was weighed each time, 30wt% methanol aqueous solution was dissolved and then purified by reverse phase chromatography, specifically, methanol and 0.1% formic acid aqueous solution by volume were used as mobile phases (the volume ratio of methanol to formic acid aqueous solution was 30:70) for elution, and then acetonitrile and 0.1% formic acid aqueous solution by volume were used as mobile phases (the volume ratio of acetonitrile to formic acid aqueous solution was 15:85) for elution, and finally 130g of ferruginous acid with a purity of not less than 98% was obtained.
[0046] The molecular formula of effluent acid is: C 26 H 24 O 13 ;Molecular weight: 544.12;
[0047] The spectral data of Erigeron acid are as follows:
[0048]
[0049] IR(KBr tablet, cm -1 ): 2973-3424,1688,1631,1445,1519,1604,1283,1163.
[0050] UVλmax(nm)(logε):329.50(0.5185),302.00(0.4003),244.00(0.3072),217.50(0.4546),203.00(0.3993).
[0051] Eupatorium sour 1 H-NMR data are as follows:
[0052] 1 H-NMR(600MHz,CD3COCD3,ppm,J in Hz): 2.45(1H,dd,J=15.4,5.5,H-3α), 2.29(1H,d,J=15.5), 4.58(1H,dd,J=8.7,5.5,H-4), 5.45(1H,dd,J=12.2,8.7,H-5), 4.60(1H,d d,J=10.0,5.5,H-6),4.62(1H,ddd,J=13.5,10.0,8.7,H-7),4.63(1H,dd,J=10.0,2.4,H-8a),5.30(1H,t,J=5.5,H-8b);7.09(1H,d,J= 1.9,H-2'),6.87(1H,d,J=7.6,H-5'),7.10(1H,dd,J=7.6,1.9,H-6'),7.69(1H,d,J=15.9,H-7'),6.58(1H,d,J=15.9,H-8'),7.31(1H ,1H,d,J=1.9,H-2”),6.86(1H,d,J=8.1,H-5”),7.09(1H,dd,J=8.1,1.9,H-6”),7.58(1H,d,J=15.8,H-7”),6.38(1H,d,J=15.8,H-8”).
[0053] Eupatorium sour 13 C-NMR data are as follows:
[0054] 13C-NMR(100.62Hz,CD3COCD3,ppm):168.7(C-1),103.9(C-2),38.5(C-3),67.8(C-4),67.1(C-5), 80.6(C-6),77.8(C-7),63.7(C-8),127.9(C-1'),115.4(C-2'),146.4(C-3'),148.8(C-4'),116. 4(C-5'),116.4(C-6'),145.9(C-7'),115.4(C-8'),167.7(C-9'),127.7(C-1”),115.3(C-2”),14 6.3(C-3”),148.7(C-4”),116.3(C-5”),122.8(C-6”),145.9(C-7”),115.3(C-8”),167.2(C-9”).
[0055] The method for determining the absolute configuration of effluent acid in the embodiments of the present invention is as follows:
[0056] Based on NMR technology, the basic structure and relative configuration of ferulate acid can be determined, but its absolute configuration cannot be determined. The present invention provides a method for synthesizing a methylated derivative of ferulate acid, and the configuration of the derivative is determined by methyl esterification, thereby determining the absolute configuration of ferulate acid; the reaction formula involved is as follows:
[0057]
[0058] Dissolve ferruginic acid (1 eq) in a dried dimethylformamide (DMF) solution, add iodomethane (10 eq) and K2CO3 (10 eq) in sequence with stirring, react at 40°C under N2 protection for 5 h, and detect the reaction by thin layer chromatography (TLC). After the reaction is completed, add 1 mol / L HCl to the reaction system under ice-water bath conditions to quench the reaction, then extract with ethyl acetate, wash the ethyl acetate layer with saturated brine, and dry with anhydrous Na2SO4 to remove water. The dried ethyl acetate layer is concentrated under reduced pressure and separated by silica gel column chromatography (49 / 1, dichloromethane / methanol, v / v) to obtain 3',4',3",4"-tetramethoxyferruginic acid methyl ester product, and culture single crystals in dichloromethane-methanol (1 / 1, v / v) system to obtain 3',4',3",4"-tetramethoxyferruginic acid methyl ester and dichloromethane composite crystals. The data are shown in Table 1:
[0059] Table 1 X-ray single crystal diffraction data of fleabane acid derivatives
[0060]
[0061]
[0062] Figure 1 For the X-ray single crystal structure of the methyl esterified derivative of feliganoic acid in the asymmetric unit, the displacement ellipsoids were plotted at a probability level of 30%; Figure 2 For the X-ray single crystal structure of the methyl esterified derivative of feliganoic acid observed by the atomic labeling method, the displacement ellipsoids were plotted at a probability level of 30%; Figure 3 This is the molecular arrangement diagram of the methyl ester derivative of felibacteric acid (hydrogen bonds are represented by dotted lines).
[0063] According to the analysis of X-ray single crystal diffraction data, the absolute configuration of 3',4',3",4"-tetramethoxy ferulate acid methyl ester is 2S,4R,5R,6S,7R. Through chemical reaction correlation, the chiral center did not change during the reaction, so ferulate acid is (2S,4R,5R,6S,7R)-4,8-di[(E)-caffeoyloxy]-2,7-anhydro-3-deoxy-D-manno-2-octulos onic Acid].
[0064] Application Example 1
[0065] Take 154 mg of sodium bicarbonate and dissolve it in water for injection; add 1 g of ferulate acid and dissolve it by ultrasonic treatment; then add 1 g of dry dew alcohol, adjust the pH value to 3.5-4 with hydrochloric acid, filter with a microporous filter membrane, add water for injection to a total volume of 100 mL, divide it into 100 bottles, and freeze-dry to obtain ferulate acid lyophilized agent.
[0066] Test Example 1
[0067] The present invention provides a rat permanent middle cerebral artery occlusion model (permanent middle cerebral occlusion, pMCAO) to evaluate the activity of felibacic acid on cerebral ischemic injury. The felibacic acid lyophilized agent obtained in Application Example 1 is used as an experimental group, and scutellarin (Deng) and butylphthalide (Ding) are used as a positive control group, and the following experimental scheme is used:
[0068] Referring to the methods of Longa (Stroke, 1989, 20, 84-91) and Cao Yongjun (Chinese Journal of Applied Physiology, 2001, 17, 198-200), the suture method was used to establish the MCAO / R model in rats. The establishment method was as follows: qualified male rats (weight 280-300 g) were anesthetized with a respiratory anesthesia machine and tied to the operating table. The neck of the rats was shaved and routinely disinfected. An incision of about 1.5 cm was made in the middle of the neck. The right common carotid artery (CCA) was separated using ophthalmic forceps, and the internal carotid artery (ICA) and external carotid artery (ECA) were freed. The CCA and ICA were carefully separated to avoid damaging the vagus nerve. The proximal end of the CCA and ICA were clamped. Two surgical knots were tied at 5 mm from the bifurcation of the ECA, and an incision was made between the two surgical knots. The suture was inserted and the direction of the suture was adjusted. The suture was gently pushed toward the intracranial direction. It was observed to enter the ICA, and then it was pushed forward again. When it encountered slight resistance, it was stopped. At this time, the insertion depth of the suture was usually 1.8 to 2 cm (the bifurcation of the ECA and ICA was the starting point). The head of the suture had passed through the beginning of the middle cerebral artery (MCA) and entered the thinner anterior cerebral artery (ACA). The time at this moment was recorded, the surgical knot was tied tightly, the excess thread was cut off, the skin was sutured, and the rat was put back into the mouse cage. Drug administration after ischemia.
[0069] TTC (2,3,5-triphenyltetrazolium chloride) staining: After MCAO ischemia, rats in different experimental groups were given drugs, and the rat heads were cut off 6h or 24h later, the olfactory bulb, cerebellum and brainstem were removed, and slices were made in an artificial cerebrospinal fluid environment, with a slice thickness of 1mm. The slices were immersed in a 2.5wt% TTC solution, incubated and stained at 37°C for 15min, and then fixed in a 4wt% PFA (4wt% paraformaldehyde fixative) for 15min, and then photographed.
[0070] Detection index: TTC staining image analysis was performed using Image J software to calculate the area of ischemic area that appeared white after TTC staining. The slice with the largest ischemic area on one side after each brain tissue slice was defined as the maximum ischemic area on that side. The ischemic volume was calculated based on the thickness of each brain slice: ischemic volume = sum of ischemic areas × brain slice thickness.
[0071] Statistical analysis: Each batch of experimental data was counted separately, and after normalization with the average value of each batch of saline group as the standard, the six batches of data were combined for statistical analysis. SPSS26.0 software was used to perform one-way ANOVA on each batch and normalized combined data, and then LSD (Least significant difference) was used for comparison between groups. P<0.05 was the standard for statistically significant differences, and the results were expressed as mean ± standard error. GraphpadPrism 9.0 was used to draw statistical graphs.
[0072] According to the above experimental scheme, pharmacological experiments were carried out on the lyophilized preparation of felibacteric acid obtained in Application Example 1 at different doses, using scutellarin (Deng) and butylphthalide (Ding) as positive control drugs, respectively. The results are as follows:
[0073] (1) TTC staining 24 hours after MCAO model
[0074] Figure 4 This is the TTC staining result of MCAO model 24 hours later.
[0075] (2) 24hTTC brain ischemia volume results in MCAO rat model
[0076] According to the method of calculating ischemic volume, the ischemic volume of each group of animals was statistically analyzed, and the specific data are shown in Table 2. The positive control drug scutellarin group and the positive control drug butylphthalide group were compared with the normal saline group, and it was found that the brain ischemic volume of the animals in the positive control drug scutellarin group and the positive control drug butylphthalide group had a decreasing trend compared with the normal saline group, but there was no statistical significance (P>0.05); the brain ischemic volume of the animals in the test product lyophilized febrile acid group was compared with the normal saline group, and the brain ischemic volume decreased in a dose-dependent manner, and the brain ischemic volume of the animals in the lyophilized febrile acid (50 mg / kg) group was significantly smaller than that in the normal saline group (P<0.05).
[0077] Table 2 TTC brain ischemic volume in MCAO rat model at 24h
[0078]
[0079] (3) Results of 24hTTC brain ischemic volume ratio in MCAO rat model
[0080] According to the method of calculating the ratio of ischemic volume to total brain volume, the ischemic volume ratio of each group of animals was statistically analyzed, and the specific data are shown in Table 3. The positive control drug scutellarin group and the positive control drug butylphthalide group were compared with the normal saline group, and it was found that the brain ischemic volume ratio of animals in the positive control drug scutellarin group and the positive control drug butylphthalide group had a decreasing trend compared with the normal saline group, but there was no statistical significance (P>0.05); the test product lyophilized febrifuge acid groups were compared with the normal saline group, and the brain ischemic volume ratio decreased in a dose-dependent manner, and the brain ischemic volume of animals in the lyophilized febrifuge acid (50 mg / kg) group was significantly smaller than that in the normal saline group (P<0.05).
[0081] Table 3 The proportion of TTC brain ischemic volume in MCAO rat model at 24h
[0082]
[0083] (4) Results of 24hTTC brain ischemic volume ratio in MCAO rat model
[0084] According to the method of calculating the ratio of ischemic volume to total brain volume, the ischemic volume ratio of each group of animals was statistically analyzed, and the specific data are shown in Table 4. Compared with the saline group, the positive control scutellarin group and the positive control butylphthalide group showed a decreasing trend in the brain ischemic volume ratio of animals in the positive control scutellarin group and the positive control butylphthalide group compared with the saline group, but there was no statistical significance (P>0.05); compared with the saline group, the groups of the test product lyophilized febrile acid showed a dose-dependent decrease in the brain ischemic volume ratio, and the brain ischemic volume of animals in the lyophilized febrile acid (50 mg / kg) group was significantly smaller than that in the saline group (P<0.05).
[0085] Table 4 The proportion of TTC brain ischemic volume in MCAO rat model at 24h
[0086]
[0087] (5) Results of 24h TTC normalized cerebral ischemia volume in MCAO rat model
[0088] In order to reduce the impact of batch variation on the experimental results, each batch of data was normalized and combined with the average value of the saline group of the batch as 100%. The specific data are shown in Table 5. Under this detection system, when the positive control drug scutellarin group was compared with the normal saline group, the cerebral ischemic volume of the animals showed a decreasing trend but no statistical difference (P>0.05); when the positive control drug butylphthalide group was compared with the normal saline group, the cerebral ischemic volume of the animals in the butylphthalide group was significantly smaller than that in the normal saline group (P<0.05); when the test product lyophilized febrile acid groups were compared with the normal saline group, there was no significant difference in the cerebral ischemic volume of the animals in the lyophilized febrile acid (5 mg / kg) group (P>0.05), the cerebral ischemic volume of the animals in the lyophilized febrile acid (25 mg / kg) group was significantly smaller than that in the normal saline group (P<0.05), and the cerebral ischemic volume of the animals in the lyophilized febrile acid (50 mg / kg) group showed a decreasing trend compared with the normal saline group, but there was no statistical significance (P>0.05).
[0089] Table 5 TTC normalized cerebral ischemic volume in MCAO rat model at 24h
[0090]
[0091] (6) Results of normalized cerebral ischemic volume ratio of MCAO rat model at 24hTTC
[0092] The experimental data were normalized with the average value of the saline group, and the specific data are shown in Table 6. Under this detection system, there was no significant difference in the proportion of cerebral ischemia volume in the animals of the positive control drug scutellarin group compared with the saline group (P>0.05); the proportion of cerebral ischemia volume in the animals of the butylphthalide group was significantly smaller than that in the saline group (P<0.05); there was no significant difference in the proportion of cerebral ischemia volume in the animals of the lyophilized felibactin (5 mg / kg) group compared with the saline group (P>0.05), the proportion of cerebral ischemia volume in the animals of the lyophilized felibactin (25 mg / kg) group was significantly smaller than that in the saline group (P<0.05), and the proportion of cerebral ischemia volume in the animals of the lyophilized felibactin (50 mg / kg) group showed a decreasing trend compared with the saline group, but there was no statistical significance (P>0.05).
[0093] Table 6 Percentage of normalized cerebral ischemic volume in MCAO rat model at 24hTTC
[0094]
[0095]
[0096] (7) Results of the maximum area of normalized cerebral ischemia in MCAO rat model at 24hTTC
[0097] The experimental data were normalized with the average value of the saline group, and the specific data are shown in Table 7. Under this detection system, there was no significant difference in the maximum area of cerebral ischemia of the animals in the positive control drug scutellarin group compared with the saline group (P>0.05); the maximum area of cerebral ischemia of the animals in the positive control drug butylphthalide group compared with the saline group was reduced compared with the saline group, but there was no statistical significance (P>0.05); the maximum area of cerebral ischemia of the animals in the lyophilized felibactin (5 mg / kg) group was compared with the saline group, and the maximum area of cerebral ischemia of the animals in the lyophilized felibactin (25 mg / kg) group was significantly smaller than that in the saline group (P<0.05), and the maximum area of cerebral ischemia of the animals in the lyophilized felibactin (50 mg / kg) group showed a decreasing trend compared with the saline group, but there was no statistical significance (P>0.05).
[0098] Table 7 Maximum area of normalized cerebral ischemia in MCAO rat model at 24h TTC
[0099]
[0100] The above experimental results show that the cerebral ischemic volume, cerebral ischemic volume proportion and maximum cerebral ischemic area of animals in the lyophilized febrile acid (25 mg / kg) group were significantly smaller than those in the normal saline group (P<0.05). The cerebral ischemic volume of animals in the lyophilized febrile acid (50 mg / kg) group was significantly reduced compared with the normal saline group. Lyophilized febrile acid (25 mg / kg) has a significant activity in reducing ischemic damage, which is better than breviscapine and equivalent to butylphthalide.
[0101] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. Use of ferulate acid in the preparation of a drug for treating ischemic stroke, wherein the ferulate acid has a structure as shown in Formula I; the absolute configuration of the ferulate acid is (2S, 4R, 5R, 6S, 7R)-4,8-dicaffeoyl-2,7-anhydro-3-deoxy-D-manno-2-octulose acid, and its English name is (2S, 4R, 5R, 6S, 7R)-4,8-di[(E)-caffeoyloxy]-2,7-anhydro-3-deoxy-D-manno-2-octulos onic Acid; 2. The use according to claim 1, It is characterized in that The extraction method of the ferulate acid comprises the following steps: Extracting Erigeron breviscapus with 70-95wt% ethanol aqueous solution to obtain a total extract; The total extract is loaded onto a macroporous resin column, and eluted with water and 25 wt% ethanol aqueous solution in sequence, and the eluate obtained when eluted with 25 wt% ethanol aqueous solution is collected; the macroporous resin used in the macroporous resin column is DM130; The eluate obtained when eluting with the 25wt% ethanol aqueous solution is diluted with water, the obtained dilution is loaded onto a microporous resin column, eluted with 10wt% ethanol aqueous solution and 20wt% ethanol aqueous solution in sequence, and the eluate obtained when eluting with the 20wt% ethanol aqueous solution is collected and concentrated to dryness to obtain a concentrate; the microporous resin used in the microporous resin column is HP20SS; The concentrate is sequentially purified by reverse phase chromatography using methanol and 0.1-0.3 vol% formic acid aqueous solution in a volume ratio of 30:70 and acetonitrile and 0.1 vol% formic acid aqueous solution in a volume ratio of 15:85 as mobile phases to obtain felibacic acid; the chromatographic column used for the reverse phase chromatography purification is a dynamic axial compression column; the filler used in the dynamic axial compression column is C-18 reverse separation material.
3. The use according to claim 2, It is characterized in that The conditions for extracting Erigeron breviscapus with 70-95wt% ethanol aqueous solution include: the number of extractions is 3 times, the extraction time is 2h each time, the extraction temperature is reflux temperature each time, and the usage ratio of the 70-95wt% ethanol aqueous solution to Erigeron breviscapus is 700L:100kg each time.
4. The use according to claim 2, It is characterized in that The concentration of ethanol in the diluent is 12.5 wt %.
5. A drug for treating ischemic stroke, comprising felibacic acid and a pharmaceutically acceptable excipient, wherein the felibacic acid has a structure as shown in Formula I; the absolute configuration of the felibacic acid is (2S,4R,5R,6S,7R)-4,8-dicaffeoyl-2,7-anhydro-3-deoxy-D-manno-2-octulose acid, and its English name is (2S,4R,5R,6S,7R)-4,8-di[(E)-caffeoyloxy]-2,7-anhydro-3-deoxy-D-manno-2-octulos onic Acid; 6. The drug for treating ischemic stroke according to claim 5, It is characterized in that The dosage form of the medicine for treating ischemic stroke is injection or lyophilized preparation.
